Op­ti­miz­ing clin­i­cal out­comes for chal­leng­ing mol­e­cules with lipid-based drug de­liv­ery

Pic­tured: Op­tiShell. All im­ages cour­tesy of Catal­ent Phar­ma So­lu­tions. © 2017 Catal­ent, Inc. All rights re­served

Im­ple­ment­ing a bioavail­abil­i­ty en­hanc­ing for­mu­la­tion ap­proach can pos­i­tive­ly im­pact safe­ty, ef­fi­ca­cy, and pa­tient ad­her­ence, lead­ing to suc­cess­ful clin­i­cal out­comes.  This ar­ti­cle takes an in-depth look at how lipid-based drug de­liv­ery sys­tems (LB­DDS) can be used as a bioavail­abil­i­ty en­hanc­ing tech­nol­o­gy, as well as the soft­gel dosage form for their de­liv­ery, in or­der to achieve suc­cess­ful clin­i­cal out­comes.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER